Amneal Pharmaceuticals, Inc.

AMRX

US03168L1052

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
6.66 ^USD	+2.94%		-1.48%	+9.72%

May. 06	Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $8 From $6.25, Maintains Buy Rating	MT
May. 03	Truist Securities Raises Amneal Pharmaceuticals' Price Target to $9 From $7, Maintains Buy Rating	MT

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2022

November 04, 2022 at 06:25 am EDT

Amneal Pharmaceuticals, Inc. reaffirmed earnings guidance for the year 2022. For the period, the company expects net revenue of $2.15 billion - $2.25 billion.

Latest news about Amneal Pharmaceuticals, Inc.

Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $8 From $6.25, Maintains Buy Rating	May. 06	MT
Truist Securities Raises Amneal Pharmaceuticals' Price Target to $9 From $7, Maintains Buy Rating	May. 03	MT
Drugmaker Amneal agrees to $270 million U.S. opioid settlement	May. 03	RE
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	May. 03	MT
Transcript : Amneal Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 03, 2024	May. 03
Amneal Pharmaceuticals Q1 Adjusted Earnings, Revenue Climb	May. 03	MT
(AMRX) AMNEAL PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $0.53 - $0.63	May. 03	MT
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Reports Q1 Revenue $659.2M, vs. Street Est of $619M	May. 03	MT
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Posts Q1 EPS $0.14, vs. Street Est of $0.09	May. 03	MT
North American Morning Briefing : Apple, Amgen -2-	May. 03	DJ
Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for Full Year 2024	May. 03	CI
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 03	CI
Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	Apr. 24	MT
Amneal Pharmaceuticals Shares Rise 9% After FDA Approves Naloxone Spray	Apr. 24	DJ
Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose	Apr. 24	CI
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	Apr. 18	MT
Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll	Apr. 17	CI
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	Apr. 12	MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds	Apr. 12	MT
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision	Apr. 08	RE
Bausch Health Up Near 0.4% In US Premarket After Announcing Patent Lawsuit Against Amneal Pharmaceuticals	Apr. 08	MT
North American Morning Briefing : Inflation Data, -2-	Apr. 08	DJ
Amneal Pharma Gets FDA Nod for Infection Fighting Drug Combination	Mar. 25	DJ
Amneal Pharmaceuticals Receives FDA Approval for Ear Infection Treatment	Mar. 25	MT
Amneal Pharmaceuticals, Inc Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension	Mar. 25	CI

Chart Amneal Pharmaceuticals, Inc.

Duration

Period

More charts

Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Companyâs Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segmentâs portfolio includes central nervous system disorders (Parkinsonâs disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Companyâs AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.

Sector

Pharmaceuticals

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Amneal Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.66 USD

Average target price

8.25 USD

Spread / Average Target

+23.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AMNEAL PHARMACEUTICALS, INC.	+9.72%	2.06B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals